A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 319 participants.

Also called NCT07835971

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 319 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07835971
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07835971. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-24 (actual); primary completion 2026-09-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential Hypertension
Condition
Hypertension
Intervention (Drug)
GW906
Intervention (Drug)
Placebo
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07835971
Content hash
47ee9c2c5af446ce501f66295a1872b6ce0ea8d671d08900fbb17be706108b52